Drug Profile
AMP 224
Alternative Names: 2661380; AMP-224; AMP-244; GSK-2661380Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Amplimmune
- Developer AstraZeneca; National Cancer Institute (USA)
- Class Antineoplastics; Immunoglobulin fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Solid tumours
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Metastatic disease) in USA (IV)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (Parenteral)
- 01 Nov 2014 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Combination therapy) in USA (IV)